A study of dapagliflozin in Chinese adult patients with chronic kidney disease

Trial Identifier: D169AC00008
Sponsor: AstraZeneca
Start Date: August 2024
Primary Completion Date: April 2027
Study Completion Date: April 2027
Condition: Chronic Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100034
CN Beijing, CN, 100191
CN Beijing, CN, 100068
CN Beijing, CN, 100044
CN Beijing, CN, 102206
CN changchun, CN, 130021
CN Dongguan, CN, 523059
CN Foshan, CN, 528308
CN Fuyang, CN, 236012
CN Fuzhou, CN, 350001
CN Ganzhou, CN, 341099
CN Harbin, CN, 150000
CN Hefei, CN, 230601
CN Hengyang, CN, 421001
CN Huaian, CN, 223399
CN Huizhou, CN, 516001
CN Jilin, CN, 132011
CN Jinan, CN, 250014
CN Jining, CN, 272029
CN Lanzhou, CN, 730000
CN Linyi, CN, 276199
CN Nanchang, CN, 330006
CN Nanjing, CN, 210029
CN Nanning, CN, 530021
CN Ningbo, CN, 315010
CN shanghai, CN, 200090
CN Shenzhen, CN, 518036
CN Suzhou, CN, 215004
CN Taian, CN, 271099
CN Tianjin, CN, 300121
CN Wuhu, CN, 241000
CN Wuxi, CN, 214023
CN Xiamen, CN, 361004
CN XIAN, CN, 710000